GENE ONLINE|News &
Opinion
Blog

2020-09-20| IPOTechnology

Magic Mushrooms Have the Potential as Depression Therapy?Compass Pathways Filing for IPO

by ray
Share To

Compass Pathways, a British company, established in 2016. Since two out of three founders have a mental illness family history, the company bears a deepened understanding of the lack of mental disorder treatments. This firmed the founders’ decision to establish the company and focus on benefiting more depression-related patients through innovative, supportive therapy.

By Ray Jhang, Ph.D. Candidate

With the prevalence of psychotic diseases rises dramatically, an increasing number of patients are suffering, while effective medical relief and compact guidelines are far from perfect. Limited medical support spurs Compass Pathways to come up with a synthesized compound made of Psilocybin extracted from over 200 kinds of psilocybe fungi (Known as “Magic Mushrooms”). Synthesized Psilocybin (COMP 360) along with FDA approved therapists, could provide patients with medical assistance aside from standard treatments.

Related Article: FDA Approves New Drug for Specific Treatment of Postpartum Depression

Psilocybin Therapy

A licensed therapist would conduct supportive treatment. After taking Psilocybin capsules, patients will be asked to explore self-consciousness and mental status in a well-designed environment with music. The entire therapy takes up 6-8 hours and carries out in the form of a trusting group built up by patients with qualified therapists’ supervision.

FDA praised psilocybin therapy in 2018 as “an innovative therapy design for drug-resistant depression”. Early experiments have proven that Psilocybin-based therapy is safe and effective for depression, anxiety, substance abuse, and other mental illnesses. Compass Pathways is now conducting phase 2b clinical trials on 216 patients with treatment-resistant depression at 20 enroll sites throughout Europe and the U.S. Psilocybin would serve as supportive treatment combined with serotonin reuptake inhibitors. Further clinical observation and studies would be performed to evaluate psilocybin’s safety and efficacy of psilocybin and determine the adequate dosage.

Nevertheless, malignant side effects are still seen in phase II clinical trial. Two out of 216 patients performed therapy-related adverse symptoms. One displayed adjustment disorder after one month of therapy while the other had suicidal attempts, both of whom have thus withdrawn the clinical trial.

Given the company’s promising and potential importance in treating depression, Compass Pathway has filed an IPO with Nasdaq. It has successively raised about US$100 million, and one of the famous investors in Silicon Valley tycoon is Peter Thiel, the co-founder of PayPal and the largest early investor of Facebook. The successful fundraising of Compass Pathways may show that pharmaceutical investors are optimistic about the future of this therapy.

Related Article: Do You Need to Switch Antidepressants? Your Brainwaves Can Tell.

References:

1.https://geneonline.news/index.php/2020/09/05/compass-pathways-ipo-psilocybin-magic-mushroom-paypalfounder/

2.https://compasspathways.com/our-research/psilocybin-therapy/our-clinical-trials/treatment-resistant-depression/

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
R&D
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder
2024-11-19
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top